Abstract
This analysis aimed to evaluate the cost effectiveness of pembrolizumab in combination with chemotherapy (paclitaxel, nab-paclitaxel or gemcitabine+carboplatin) vs chemotherapy as first-line treatment in patients with locally recurrent unresectable or metastatic triple negative breast cancer (mTNBC) whose tumors express programmed death ligand-1 (PD-L1) (combined positive score (CPS) ≥10), from a US third-party public healthcare payer perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
